dc.contributor.author | Pavlidis, Nicholas | en |
dc.contributor.author | Petrakis, Dimitrios | en |
dc.contributor.author | Golfinopoulos, Vassilis | en |
dc.contributor.author | Pentheroudakis, George | en |
dc.creator | Pavlidis, Nicholas | en |
dc.creator | Petrakis, Dimitrios | en |
dc.creator | Golfinopoulos, Vassilis | en |
dc.creator | Pentheroudakis, George | en |
dc.date.accessioned | 2018-06-22T09:54:16Z | |
dc.date.available | 2018-06-22T09:54:16Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42274 | |
dc.description.abstract | There is a general conception among oncologists that CUP patients behave poorly to treatment and carry a dismal survival. In this paper we are trying to elucidate the different groups of CUP patients and to describe in details the diagnostic and therapeutic management of the prognostically favorable patients. Clinicians should be aware that the favorable CUP cases must be treated according to recent guidelines with either specific locoregional and/or systemic therapy and that they commonly enjoy a long survival. Survival data of 219 CUP patients treated at Ioannina University Hospital from 1995 until 2011 are also presented. © 2012 Elsevier Ireland Ltd. | en |
dc.language.iso | eng | en |
dc.source | Critical reviews in oncology/hematology | en |
dc.subject | Female | en |
dc.subject | Male | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Etoposide | en |
dc.subject | Human | en |
dc.subject | Neoplasms | en |
dc.subject | Humans | en |
dc.subject | Cancer survival | en |
dc.subject | Taxane derivative | en |
dc.subject | Cytoreductive surgery | en |
dc.subject | Review | en |
dc.subject | Cancer prognosis | en |
dc.subject | Survival | en |
dc.subject | Bone metastasis | en |
dc.subject | Melanoma | en |
dc.subject | Platinum complex | en |
dc.subject | Trastuzumab | en |
dc.subject | Clinical feature | en |
dc.subject | Histopathology | en |
dc.subject | Lymph node dissection | en |
dc.subject | Lymph node metastasis | en |
dc.subject | Cancer incidence | en |
dc.subject | Colon cancer | en |
dc.subject | Adenocarcinoma | en |
dc.subject | Cancer of unknown primary site | en |
dc.subject | Unknown primary | en |
dc.subject | Prostate specific antigen | en |
dc.subject | Neuroendocrine tumor | en |
dc.subject | Cancer of unknown primary | en |
dc.subject | Somatostatin derivative | en |
dc.subject | Head and neck squamous cell carcinoma | en |
dc.subject | Androgen deprivation therapy | en |
dc.subject | Axillary nodal metastasis | en |
dc.subject | Favorable subsets | en |
dc.subject | Immunochemistry | en |
dc.subject | Melanoma of unknown primary | en |
dc.subject | Neuroendocrine carcinoma of unknown primary | en |
dc.subject | Peritoneum tumor | en |
dc.subject | Poorly differentiated carcinoma with midline distribution | en |
dc.subject | Primary peritoneal adenocarcinoma | en |
dc.subject | Squamous cell carcinoma involving cervical lymph node | en |
dc.subject | Survivors | en |
dc.title | Long-term survivors among patients with cancer of unknown primary | en |
dc.type | info:eu-repo/semantics/article | |
dc.identifier.doi | 10.1016/j.critrevonc.2012.02.002 | |
dc.description.volume | 84 | |
dc.description.issue | 1 | |
dc.description.startingpage | 85 | |
dc.description.endingpage | 92 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.contributor.orcid | Pentheroudakis, George [0000-0002-6632-2462] | |
dc.gnosis.orcid | 0000-0002-2195-9961 | |
dc.gnosis.orcid | 0000-0002-6632-2462 | |